CFO
ABBV icon

CVA Family Office’s AbbVie ABBV Stock Holding History

CVA Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
4,882
-304
-6% -$65.4K 0.11% 107
2026
Q1 		$1.13M Buy
5,186
+682
+15% +$151K 0.12% 106
2025
Q4 		$1.03M Buy
4,504
+10
+0.2% +$2.28K 0.12% 103
2025
Q3 		$1.04M Buy
4,494
+82
+2% +$16.7K 0.13% 100
2025
Q2 		$819K Sell
4,412
-36
-0.8% -$6.69K 0.12% 113
2025
Q1 		$932K Buy
4,448
+383
+9% +$74.5K 0.14% 103
2024
Q4 		$722K Buy
4,065
+220
+6% +$40.4K 0.11% 119
2024
Q3 		$759K Buy
3,845
+152
+4% +$28.4K 0.12% 114
2024
Q2 		$633K Buy
3,693
+224
+6% +$37.1K 0.11% 120
2024
Q1 		$632K Buy
3,469
+103
+3% +$17.8K 0.11% 119
2023
Q4 		$522K Sell
3,366
-12
-0.4% -$1.75K 0.1% 127
2023
Q3 		$504K Buy
3,378
+465
+16% +$68.3K 0.11% 124
2023
Q2 		$392K Sell
2,913
-178
-6% -$26.1K 0.08% 141
2023
Q1 		$493K Buy
3,091
+240
+8% +$36.7K 0.11% 123
2022
Q4 		$461K Sell
2,851
-25
-0.9% -$3.83K 0.11% 121
2022
Q3 		$386K Sell
2,876
-60
-2% -$8.61K 0.1% 122
2022
Q2 		$450K Buy
2,936
+150
+5% +$22.9K 0.12% 104
2022
Q1 		$452K Buy
2,786
+685
+33% +$99.5K 0.11% 107
2021
Q4 		$284K Buy
2,101
+1,801
+600% +$213K 0.07% 139
2021
Q3 		$26K Sell
300
-1,846
-86% -$211K 0.02% 240
2021
Q2 		$242K Buy
2,146
+526
+32% +$59.2K 0.07% 142
2021
Q1 		$175K Buy
1,620
+1,320
+440% +$141K 0.07% 129
2020
Q4 		$32K Hold
300
– – 0.02% 232
2020
Q3 		$26K Buy
+300
New +$28.2K 0.02% 240

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CVA Family Office's ABBV Position: Q2 2026 in Review

CVA Family Office reduced its AbbVie (ABBV) stake by 5.9% in Q2 2026, selling an estimated $65.4K and leaving 4,882 shares worth $1.23M. The position accounts for 0.11% of the portfolio, ranked #107.

CVA Family Office first reported a position in ABBV in Q3 2020 and has held it in 24 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • CVA Family Office held 4,882 shares of AbbVie worth $1.23M as of Q2 2026.
  • CVA Family Office sold 304 AbbVie shares in Q2 2026, an estimated $65.4K.
  • AbbVie made up 0.11% of CVA Family Office's portfolio in Q2 2026, its #107 holding.
  • CVA Family Office first reported a position in AbbVie in Q3 2020 and has held it in 24 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.